ENSCW — Ensysce Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1716947 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,562,230 | -3,556,415 | 2,167,803 | 745,482 | 2,836,815 |
| Dec 2025 | 0 | — | -2,781,825 | -2,767,648 | 7,452,479 | 4,310,354 | 4,567,729 |
| Sep 2025 | 0 | — | -3,741,095 | -3,729,128 | 3,179,464 | 1,673,218 | 2,304,750 |
| Jun 2025 | 0 | — | -1,750,515 | -1,733,351 | 5,574,455 | 2,211,575 | 2,514,043 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,599,805
Investing CF
$0
Financing CF
$7,416,439
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-143,276,414
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,768,195
Pretax Income TTM
$-11,787,029
Interest Exp TTM
$18,834
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,707,877
EBITDA
—
Free Cash Flow
$-5,554,856
Enterprise Value
—
Total Cash
$745,482
Total Debt
$245,849
Shares Out
—
Trailing EPS
—
Book Value
$-0.04
ROE
-1149.1%
ROA
-218.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,240,946 | -10,175,700 | 7,452,479 | 4,567,729 | — | -7,806,292 |
| Dec 2024 | 0 | -6,730,134 | -7,986,935 | 5,597,232 | 2,217,293 | — | -7,502,700 |
| Dec 2023 | 0 | -10,718,187 | -10,613,074 | 2,708,085 | 3,359,352 | — | -10,779,982 |
| Dec 2022 | 0 | -24,222,095 | -24,172,292 | 5,885,052 | 9,914,704 | — | -17,887,439 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1188.58 | — |
| JNJ | JOHNSON & JOHNSON | $618.61B | $256.98 | — |
| ABBV | AbbVie Inc. | $438.31B | $248.08 | — |
| NVSEF | NOVARTIS AG | $305.29B | $160.00 | — |
| MRK | Merck & Co., Inc. | $305.12B | $123.54 | — |
Recent Insider Activity
No insider activity indexed for this ticker.